{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:36:01Z","timestamp":1777775761123,"version":"3.51.4"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the potential benefit of chidamide maintenance therapy after induction treatment in peripheral T-cell lymphoma (PTCL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>The clinical data of 48 transplantation-ineligible patients with different PTCL subtypes who received continuous chidamide treatment after first-line therapy were collected. Progression-free survival (PFS), overall survival (OS), and safety were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 68.8% of patients were male (33\/48), the median age was 59.5 years (22~80). The pathological subtypes were angioimmunoblastic T-cell lymphoma (AITL, 43.8%), anaplastic large cell lymphoma (ALCL, 16.6%), PTCL-not otherwise specified (NOS, 25%), NK\/T-cell lymphoma (NKT, 14.6%). 35.4% (7\/48) patients had intermediate or high risk (IPI=3~5). 20 patients (41.7%) received chidamide as a maintenance treatment after achieving a complete response (CR). 57.1% (16\/28) exhibited a better response after chidamide (9 cases partial response [PR] to CR, 7 from stable disease [SD] to PR). The CR and overall response rate (ORR) were 60.4% and 93.8%, respectively. In addition, 21\/21 AITL, 10\/12 PTCL-NOS, and 8\/8 ALCL, 6\/7 NK\/T exhibited CR\/PR as the best response during the follow-up period. Meanwhile, the CR and ORR did not differ by age (&amp;lt;60 <jats:italic>vs<\/jats:italic> \u226560: 50.0% <jats:italic>vs<\/jats:italic> 70.8%, P = 0.091; and 91.7% <jats:italic>vs<\/jats:italic> 95.8%, P = 0.551). The median follow-up period was 12.8 months (3.0\u201366.6), 14 patients developed PD (29.2%), 10 of them died of lymphoma (20.8%). Totally, the 40 cases achieved CR\/PR from 1st line regimen got better PFS as well as OS than the rest 8 cases (the 1-year PFS was 80.8% <jats:italic>vs<\/jats:italic> 46.9% and the 2-year PFS was 71.9% <jats:italic>vs<\/jats:italic> 46.9%, P=0.012. the 1-year OS was 89.9% <jats:italic>vs<\/jats:italic> 72.6% and the 2-year OS was 85.9% <jats:italic>vs<\/jats:italic> 48.6%, P=0.032). No patients discontinued treatment because of adverse events. The most common toxicities were neutropenia (75.0%), anemia (79.2%), thrombocytopenia (58.3%), and anorexia (45.8%), and fatigue (43.8%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Chidamide maintenance therapy led to improvements of PFS and OS with a manageable safety profile in patients with PTCL. Further randomized studies are required to examine the role of chidamide maintenance therapy in PTCL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.875469","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:06:42Z","timestamp":1654578402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China"],"prefix":"10.3389","volume":"12","author":[{"given":"Wei","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianying","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangzhi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"B1","article-title":"A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma. The Non-Hodgkin's Lymphoma Classification Project","volume":"89","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/1746-1596-6-77","article-title":"Subtype Distribution of Lymphomas in Southwest China: Analysis of 6,382 Cases Using WHO Classification in a Single Institution","volume":"6","author":"Yang","year":"2011","journal-title":"Diagn Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","article-title":"Distribution of Lymphoid Neoplasms in China Analysis of 4,638 Cases According to the World Health Organization Classification","volume":"138","author":"Sun","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30416","article-title":"A Prospective Cohort Study of Patients With Peripheral T-Cell Lymphoma in the United States","volume":"123","author":"Carson","year":"2017","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International Peripheral T-Cell and Natural Killer\/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.186577","article-title":"The Outcome of Peripheral T-Cell Lymphoma Patients Failing First Line Therapy: A Report From the Prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","article-title":"Romidepsin for the Treatment of Relapsed\/Refractory Peripheral T Cell Lymphoma: Prolonged Stable Disease Provides Clinical Benefits for Patients in the Pivotal Trial","volume":"9","author":"Foss","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1847-5","article-title":"Phase I Study of Chidamide (CS055\/HBI-8000), a New Histone Deacetylase Inhibitor, in Patients With Advanced Solid Tumors and Lymphomas","volume":"69","author":"Dong","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2016.01024","article-title":"Development of Chidamide for Peripheral T-Cell Lymphoma, the First Orphan Drug Approved in China","volume":"5","author":"Lu","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results From a Multicenter, Open-Label, Pivotal Phase II Study of Chidamide in Refractory or Relapsed Peripheral T-Cell Lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1766-x","article-title":"Chidamide (CS055\/HBI-8000): A New Histone Deacetylase Inhibitor of the Benzamide Class With Antitumor Activity and the Ability to Enhance Immune Cell-Mediated Tumor Cell Cytotoxicity","volume":"69","author":"Ning","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1039\/C4MD00350K","article-title":"Discovery of an Orally Active Subtype-Selective HDAC Inhibitor, Chidamide, as an Epigenetic Modulator for Cancer Treatment","volume":"5","author":"Pan","year":"2014","journal-title":"MedChemComm"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/123756","article-title":"Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases With Sustained Remission","volume":"2015","author":"Fuentes","year":"2015","journal-title":"Case Rep Oncol Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000501070","article-title":"Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, With Prophylactic Leucovorin","volume":"12","author":"Kitazume","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The Role of Autologous Stem Cell Transplantation in Patients With Nodal Peripheral T-Cell Lymphomas in First Complete Remission: Report From COMPLETE, a Prospective, Multicenter Cohort Study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma for Patients in Response After Induction: An Analysis of Patients From LYSA Centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in Relapsed or Refractory Peripheral T Cell Lymphoma: A Multicenter Real-World Study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.875469\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T05:06:44Z","timestamp":1654578404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.875469\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":18,"alternative-id":["10.3389\/fonc.2022.875469"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.875469","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"article-number":"875469"}}